Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

NCT07286292 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

Interventions

DRUG: Vorasidenib

Sponsor

Institut de Recherches Internationales Servier (I.R.I.S.)